Qtrilmet Approved in the EU for Treating Type-2 Diabetes

AstraZeneca’s Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets received approval from the European Commission to improve glycemic control in adults with type-2 diabetes (T2D).

The EC granted the approval to improve glycemic control in adults with T2D when metformin, Onglyza or Forxiga does not provide adequate glycemic control, or when T2D patients are already being treated with either of the three drugs.

Qtrilmet was approved in the U.S. in May under the name Qternmet XR as an adjunct to diet and exercise to improve glycemic control in adults with T2D.